CY1114214T1 - Lys-Pro-Thr KAI Lys-Pro ΩΣ ΕΝΩΣΕΙΣ ΠΟΥ ΑΝΑΣΤΕΛΛΟΥΝ ΤΗ ΦΛΕΓΜΟΝΗ - Google Patents

Lys-Pro-Thr KAI Lys-Pro ΩΣ ΕΝΩΣΕΙΣ ΠΟΥ ΑΝΑΣΤΕΛΛΟΥΝ ΤΗ ΦΛΕΓΜΟΝΗ

Info

Publication number
CY1114214T1
CY1114214T1 CY20131100702T CY131100702T CY1114214T1 CY 1114214 T1 CY1114214 T1 CY 1114214T1 CY 20131100702 T CY20131100702 T CY 20131100702T CY 131100702 T CY131100702 T CY 131100702T CY 1114214 T1 CY1114214 T1 CY 1114214T1
Authority
CY
Cyprus
Prior art keywords
pro
lys
thr
kai
components
Prior art date
Application number
CY20131100702T
Other languages
English (en)
Inventor
Thomas Luger
Original Assignee
Thomas Luger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Luger filed Critical Thomas Luger
Publication of CY1114214T1 publication Critical patent/CY1114214T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/85—Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C12N2501/86—Melanocyte-stimulating hormone [MSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά τη χρησιμοποίηση μιας ένωσης του τύπου Lys-X, όπου Χ είναι μια υδροξυλομάδα, μια αμινομάδα, μια αλκοξυ-ομάδα, Pro ή Pro-Thr, ή ένα από φαρμακευτικής άποψης συμβατό άλας αυτών, για τη θεραπευτική αγωγή αυτοάνοσων ασθενειών, αλλεργικών αντιδράσεων και απόρριψης μοσχεύματος.
CY20131100702T 2001-02-14 2013-08-14 Lys-Pro-Thr KAI Lys-Pro ΩΣ ΕΝΩΣΕΙΣ ΠΟΥ ΑΝΑΣΤΕΛΛΟΥΝ ΤΗ ΦΛΕΓΜΟΝΗ CY1114214T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10106852A DE10106852A1 (de) 2001-02-14 2001-02-14 Entzündungshemmende Verbindungen
EP10154655.4A EP2196202B1 (de) 2001-02-14 2002-02-08 Lys-Pro-Thr und Lys-Pro als entzündungshemmende Verbindungen

Publications (1)

Publication Number Publication Date
CY1114214T1 true CY1114214T1 (el) 2016-08-31

Family

ID=7674019

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20071100596T CY1106563T1 (el) 2001-02-14 2007-05-07 Φλεγμονο-ανασταλτικες ενωσεις
CY20111100430T CY1111450T1 (el) 2001-02-14 2011-05-04 Ενωσεις που αναστελλουν τη φλεγμονη
CY20131100431T CY1114024T1 (el) 2001-02-14 2013-05-30 Ενωσεις που αναστελλουν τη φλεγμονη
CY20131100702T CY1114214T1 (el) 2001-02-14 2013-08-14 Lys-Pro-Thr KAI Lys-Pro ΩΣ ΕΝΩΣΕΙΣ ΠΟΥ ΑΝΑΣΤΕΛΛΟΥΝ ΤΗ ΦΛΕΓΜΟΝΗ

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20071100596T CY1106563T1 (el) 2001-02-14 2007-05-07 Φλεγμονο-ανασταλτικες ενωσεις
CY20111100430T CY1111450T1 (el) 2001-02-14 2011-05-04 Ενωσεις που αναστελλουν τη φλεγμονη
CY20131100431T CY1114024T1 (el) 2001-02-14 2013-05-30 Ενωσεις που αναστελλουν τη φλεγμονη

Country Status (18)

Country Link
US (4) US8003608B2 (el)
EP (6) EP2189156A1 (el)
JP (1) JP4259870B2 (el)
CN (3) CN101810847B (el)
AT (2) ATE502632T1 (el)
AU (2) AU2002253000B2 (el)
CA (1) CA2437788C (el)
CY (4) CY1106563T1 (el)
DE (3) DE10106852A1 (el)
DK (4) DK2198723T3 (el)
ES (4) ES2361422T3 (el)
HK (4) HK1140960A1 (el)
MX (1) MXPA03007255A (el)
NZ (2) NZ528191A (el)
PL (3) PL223229B1 (el)
PT (4) PT2198723E (el)
SI (4) SI2196202T1 (el)
WO (1) WO2002064131A2 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
US7341992B2 (en) * 2001-05-25 2008-03-11 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Lectin-like domain of thrombomodulin and its therapeutic use
US20090232866A1 (en) 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
WO2006009325A1 (ja) * 2004-07-23 2006-01-26 Ono Pharmaceutical Co., Ltd. メタロプロテアーゼ阻害剤
JPWO2006046746A1 (ja) * 2004-10-26 2008-05-22 味の素株式会社 内臓痛予防・治療剤
JPWO2007004613A1 (ja) * 2005-07-01 2009-01-29 味の素株式会社 炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤
EP1782819A1 (en) * 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptides and their use
DE102006003854A1 (de) * 2006-01-26 2007-08-02 Universität Duisburg-Essen Regulatorische und cytotoxische CD8+ T-Zellen
CA2703891A1 (en) * 2007-11-19 2009-05-28 Universitaetsklinikum Muenster Compositions for reducing oxidative stress and uses thereof
US9156881B2 (en) 2011-09-23 2015-10-13 Westfaelische Wilhelms-Universitaet Muenster Tripeptide KDPT for antiapoptotic treatment
KR20140136494A (ko) 2012-03-20 2014-11-28 헬릭스 바이오메딕스, 인코포레이티드 짧은 항균 지질펩티드
AU2014262517B2 (en) * 2013-05-10 2018-10-18 Southern Research Institute Compounds, compositions and methods for the treatment of diseases through inhibiting TGF-beta activity
PL3049428T3 (pl) * 2013-09-23 2019-07-31 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Tripeptydy przeciwzapalne
SG11201603440SA (en) 2013-11-07 2016-05-30 Wolff August Gmbh & Co Kg Arzneimittel Dr Storage stable lyophilized tripeptide formulations
CN107349416A (zh) * 2017-08-01 2017-11-17 中山大学 一种含三肽化合物的抗骨关节炎药物
US11629169B2 (en) * 2017-09-15 2023-04-18 Kine Sciences Co., Ltd. Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
CN111150831B (zh) * 2020-02-27 2023-06-09 广州领晟医疗科技有限公司 多肽KdPT的应用
US11793746B2 (en) * 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
CN114432421B (zh) * 2022-01-12 2024-04-12 广州领晟医疗科技有限公司 一种用于治疗急性肺损伤的KdPT多肽及其应用
CN114404562A (zh) * 2022-01-17 2022-04-29 广州领晟医疗科技有限公司 一种用于治疗骨关节炎的KdPT多肽及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000833A2 (en) * 1986-08-08 1988-02-11 Board Of Regents, The University Of Texas System Antipyretic and anti-inflammatory peptides
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
IL89770A (en) 1988-03-28 1994-12-29 British Tech Group Analgesic peptides and pharmaceutical compositions containing them and the process for the preparation of some such compounds
ES2012532A6 (es) * 1988-07-15 1990-04-01 Cusi Lab Un procedimiento para la preparacion de una solucion acuosa de b-metil-4-(2' -tienilcarbonil)fenilacetato de lisina para aplicacion topica oftalmica.
DE3844046A1 (de) * 1988-12-28 1990-07-05 Hoerrmann Wilhelm Arzneimittel, die isomere des hydroxylysins oder lysins enthalten
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
DK0513379T3 (da) * 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne
BR9405661A (pt) * 1993-01-22 1995-11-21 Pfizer Sal de lisina de 6-cloro-5-flúor-3-(2-tenoil)-2-oxindole-1-carboxamida
GB9413935D0 (en) * 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
GB9419011D0 (en) * 1994-09-21 1994-11-09 Peptech Uk Ltd Use of muramyl peptide compounds
SE9500270L (sv) * 1995-01-25 1996-09-09 A K J Medi Konsult Ab Läkemedel mot bristtillstånd
AU4861196A (en) * 1995-02-03 1996-08-21 Cosmederm Technologies Formulations and methods for reducing skin irritation
FR2733421B1 (fr) 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5939394A (en) * 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
JP3567350B2 (ja) * 1996-03-13 2004-09-22 株式会社ホーネンコーポレーション 抗脱毛症剤
JP3922594B2 (ja) 1996-03-19 2007-05-30 株式会社ノエビア 抗菌性低刺激化粧料
CA2256669A1 (en) * 1996-05-29 1997-12-04 Prototek, Inc. Prodrugs of thalidomide and methods for using same as modulators of t-cell function
US6117896A (en) * 1997-02-10 2000-09-12 Molecumetics Ltd. Methods for regulating transcription factors
JP4382880B2 (ja) * 1996-10-11 2009-12-16 興和株式会社 新規なジアミド化合物及びこれを含有する医薬
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
SE9801571D0 (sv) * 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
FR2784028B1 (fr) * 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques
JP3962166B2 (ja) * 1998-10-19 2007-08-22 株式会社資生堂 皮膚外用剤
AU1773600A (en) * 1998-12-21 2000-07-12 Aps Kbus 8 Nr. 4788 Topical treatment of skin disease
EP1150570B1 (en) * 1999-01-22 2006-07-12 The Schepens Eye Research Institute, Inc. Activation of regulatory t cells by alpha-melanocyte stimulating hormone
WO2000054750A1 (fr) * 1999-03-15 2000-09-21 Dmitry Anatolievich Starchenko Procede de correction des perturbations dans la synthese du collagene et substance bioactive de mise en oeuvre de ce procede
AU2001275930B2 (en) * 2000-07-14 2007-05-10 Eisai Inc. Alpha-msh related compounds and methods of use
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
WO2002092810A1 (fr) 2001-05-11 2002-11-21 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Peptides presentant une activite inhibitrice de cyotoxicite et procede de balayage de ces peptides

Also Published As

Publication number Publication date
PT1749524E (pt) 2011-05-25
US8003608B2 (en) 2011-08-23
EP1749524B1 (de) 2011-03-23
NZ542406A (en) 2007-04-27
HK1140960A1 (en) 2010-10-29
HK1061980A1 (en) 2004-12-10
EP2260843A2 (de) 2010-12-15
PL391988A1 (pl) 2010-09-13
PL223478B1 (pl) 2016-10-31
PL223229B1 (pl) 2016-10-31
EP2189156A1 (de) 2010-05-26
US9550807B2 (en) 2017-01-24
WO2002064131A2 (de) 2002-08-22
MXPA03007255A (es) 2005-02-14
US20150087578A1 (en) 2015-03-26
SI1749524T1 (sl) 2011-08-31
DE10106852A1 (de) 2002-09-05
PT2198723E (pt) 2013-06-12
PL391884A1 (pl) 2010-09-13
ES2411935T3 (es) 2013-07-09
DE50214981D1 (de) 2011-05-05
AU2006203622A1 (en) 2006-09-07
ES2427970T3 (es) 2013-11-05
EP2196202B1 (de) 2013-07-17
CN101810847B (zh) 2013-02-13
CN101215544B (zh) 2011-05-04
CY1111450T1 (el) 2015-08-05
EP2196202A1 (de) 2010-06-16
ES2281511T3 (es) 2007-10-01
US20040077552A1 (en) 2004-04-22
US20170087202A1 (en) 2017-03-30
SI1427405T1 (sl) 2007-08-31
CN101810847A (zh) 2010-08-25
CN1541095A (zh) 2004-10-27
HK1095538A1 (en) 2007-05-11
JP4259870B2 (ja) 2009-04-30
SI2196202T1 (sl) 2013-09-30
US8846617B2 (en) 2014-09-30
CY1106563T1 (el) 2012-01-25
JP2004533995A (ja) 2004-11-11
ATE502632T1 (de) 2011-04-15
CA2437788C (en) 2011-04-05
US20120045462A1 (en) 2012-02-23
EP1427405B1 (de) 2007-04-04
EP1749524A2 (de) 2007-02-07
ATE358475T1 (de) 2007-04-15
AU2006203622B2 (en) 2007-08-09
EP1749524A3 (de) 2007-11-28
EP1427405A2 (de) 2004-06-16
PT1427405E (pt) 2007-05-31
CN1269477C (zh) 2006-08-16
PT2196202E (pt) 2013-09-24
NZ528191A (en) 2005-11-25
WO2002064131A3 (de) 2004-04-01
EP2260843A3 (de) 2011-08-03
CA2437788A1 (en) 2002-08-22
DK1749524T3 (da) 2011-06-06
SI2198723T1 (sl) 2013-06-28
EP2198723A1 (de) 2010-06-23
DE50209873D1 (de) 2007-05-16
DK1427405T3 (da) 2007-07-02
DK2198723T3 (da) 2013-06-17
US10046020B2 (en) 2018-08-14
EP2198723B1 (de) 2013-04-10
DK2196202T3 (da) 2013-09-08
PL369526A1 (en) 2005-05-02
HK1140915A1 (en) 2010-10-29
CN101215544A (zh) 2008-07-09
CY1114024T1 (el) 2016-07-27
PL221492B1 (pl) 2016-04-29
AU2002253000B2 (en) 2006-05-25
ES2361422T3 (es) 2011-06-16

Similar Documents

Publication Publication Date Title
CY1114214T1 (el) Lys-Pro-Thr KAI Lys-Pro ΩΣ ΕΝΩΣΕΙΣ ΠΟΥ ΑΝΑΣΤΕΛΛΟΥΝ ΤΗ ΦΛΕΓΜΟΝΗ
NL300933I2 (nl) Letermovir
FR17C0003I2 (fr) Steroides comme agonistes de fxr
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
EA200500453A1 (ru) Имидазопиридины и способы их получения и применения
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
EA200401612A1 (ru) Противоаллергические средства
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
ATE230392T1 (de) Amidinophenyl-pyrrolidine, -pyrroline und - isoxazolidine und ihre derivate
EA200401114A3 (ru) Замещённые гидроксиэтиламины
ECSP055844A (es) Nuevos compuestos triciclicos
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
SE0101932D0 (sv) Pharmaceutical combinations
EA200301276A1 (ru) Новые производные сульфоновых кислот
CY1106746T1 (el) Χρηση του irbesartan για την προληψη ή τη θεραπεια της πνευμονικης υπερτασης
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
EA200501900A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
DE60216457D1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
CY1105529T1 (el) Αντικατεστημενα με θειοφαινιο παραγωγα αμυνης σαν glyt-1 αναστολεις
WO2004037166A3 (en) Therapeutic guanidines
EA200201232A1 (ru) Производные сульфонамида
ATE330938T1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen